BB
Bridgebio
BBIO·NASDAQSan Francisco CAFounded 2015400 employees
Mid CapbiotechPublicCardiologyRare Disease
Platform: Acoramidis TTR
Market Cap
$6B
All Drugs
4
Clinical Trials
6
Failed / Terminated
2
FDA Approved
0
Stock Price & Catalysts (BBIO)
Loading BBIO stock data...
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Niratenlimab | BBI-1002 | Phase 1 | 2 | CD38 | SCLC | ||
| BBI-8786 | BBI-8786 | Phase 2 | 1 | EZH2 | MDD | ||
| BBI-9525 | BBI-9525 | NDA/BLA | 2 | PLK4 | LGSHNSCC | ||
| BBI-3709 | BBI-3709 | Phase 1 | 1 | AuroraA | RB |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (6)